Drug Delivery Systems Market Analysis by Delivery System (Intra Uterine, Pro-drug Implants, Targeted Drug Delivery), by Route of Administration (Oral, Injectable, Inhalation, Ocular, Nasal), by Application (Oncology, Urology, Diabetes)- Global Industry Analysis, Share, Growth, Regional Outlook and Forecasts, 2022-2030

According to Nova one advisor, the global Drug Delivery Systems market size is expected to hit around USD 80.7 billion by 2030 from valued at USD 38 .9 Billion in 2022 and growing at a CAGR of 7.30% from 2022 to 2030.

The global drug delivery systems market is creating opportunities for major and local manufacturers to develop wide product portfolio. Additionally, collaborations among major market players for superior technological advancements in drug delivery offerings is likely to drive the global drug delivery systems market during the forecast period. Using nanotechnology, the drug can be targeted to a precise location, which makes drugs more effective and reduce the chances of possible side effects. Major manufacturers operating in the market are involved in continuous research & development activities to expand their already wide product portfolio. For instance, on September 2017, Baxter International Inc. announced the launch of DeviceVue, an asset tracking system for sigma spectrum infusion system whereas, emerging players operating in the market are also focusing on introducing new versions of their existing drug delivery devices. Continuous expansion of drug delivery systems offering in high throughput along with reduced waiting time and improved result specificity are likely to drive the global drug delivery systems during the forecast period. However, high cost associated with treatment and increase in drug recalls are likely to restrain the global drug delivery systems market during the forecast period.

Report Scope of the Drug Delivery Systems Market

Prominent Drug Delivery Systems Industry Growth Drivers

Development of Innovative Medications and Biologics to Upscale the Market Growth

Progress in various biology-related activities has created an once-in-a-lifetime chance to better understand the molecular consequences of human illnesses and develop innovative medications and biologics based on these variables.

Lipid, protein, and polymer technologies with improved lipid distribution in the body, limiting drug degradation owing to the external environment, and lowering the pace of drug clearance are among the recently identified enhanced drug delivery methods. Because modern pharmaceuticals and biologics are more efficient with a lower dosage of medications, they must be supported by sophisticated drug delivery methods to get optimum efficacy from the drug.

Advanced Drug Delivery Technologies to Widen Drug Delivery Systems Deployment

Some of the controlled and targeted oral drug delivery systems are duocap (capsule-in-a-capsule), electro capsule, and light up delivery monitoring technology (LDMT), which give a novel means of manufacturing poorly soluble chemicals and monitoring medication release rate. Advanced drug delivery technologies are being developed in order to solve solubility issues and make medications more lipid-soluble.

As a result, they may readily penetrate lipid barriers in the body, avoiding external environment concerns like photo degradation and pH fluctuations from impacting the medicine and obtaining the optimal concentration at the desired site to deliver the best therapeutic benefit. As a result, these advancements are projected to boost market growth.

Increased Acceptance of Enhanced Drug Delivery Solutions widening Growth Opportunities

According to nova one advisor, North America held the largest share of the global drug delivery system market during the past years. This pattern is likely to continue throughout the projection period, with the company maintaining its market share while increasing at a CAGR of 7.2%. However, the surge in R&D costs for sophisticated medication delivery systems in the United States is a major source of worry among important stakeholders.

Key drivers for the North American drug delivery systems market are the growing preference for self-administration of pharmaceuticals, increasing advancements in injectable drug delivery systems, the high acceptance rate of new healthcare technologies, and the high incidence of chronic illnesses. Chronic illnesses and disorders are becoming more common. Heart disease is a primary cause of mortality, imposing a massive cost on individuals, communities, healthcare professionals, and systems.

Almost half of all individuals in the United States suffer from some form of cardiovascular disease. According to the American Cancer Society, approximately 2 million new instances of cancer are predicted to be identified in the United States in 2022, with 609,000 people expected to die from cancer. Greater incidence of chronic diseases, government attempts to raise awareness about such conditions, increased R&D operations, and the launch of improved drug delivery technologies will all help to boost the United States market during the forecast period.

Some of the prominent players in the Drug Delivery Systems Market include:

• Boston Scientific Corporation
• Johnson and Johnson Services, Inc.
• Pfizer, Inc.
• Baxter International, Inc.
• Amgen, Inc.
• Novartis AG
• F. Hoffmann La-Roche Ltd
• Bayer AG.

Segments Covered in the Report

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2017 to 2030. For this study, Nova one advisor, Inc. has segmented the global Drug Delivery Systems market

• Drug Delivery Systems by Delivery System
• Intra Uterine Implants
• Pro-drug Implants
• Polymeric Drug Delivery
• Targeted Drug Delivery
• Drug Delivery Systems by Route of Administration
• Oral
• Injectable
• Inhalation
• Transdermal
• Ocular
• Nasal
• Topical
• Drug Delivery Systems by Application
• Infectious Disease
• Oncology
• Ophthalmology
• Urology
• Diabetes
• CNS
• Others

By Geography

North America

• U.S.
• Canada

Europe

• Germany
• France
• United Kingdom
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• Southeast Asia
• Rest of Asia Pacific

Latin America

• Brazil
• Rest of Latin America

Middle East & Africa (MEA)

• GCC
• North Africa
• South Africa
• Rest of Middle East & Africa

Key Benefits for Stakeholders

• This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the global Drug Delivery Systems industry analysis from 2022 to 2030 to identify the prevailing Drug Delivery Systems industry opportunity.
• The market research is offered along with information related to key drivers, restraints, and opportunities.
• Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
• In-depth analysis of the global Drug Delivery Systems industry segmentation assists to determine the prevailing market opportunities.
• Major countries in each region are mapped according to their revenue contribution to the global market.
• Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
• The report includes the analysis of the regional as well as global Drug Delivery Systems industry trends, key players, market segments, application areas, and market growth strategies.